Clinical trials: Bioavailability and Pharmacokinetics
Healthy Volunteer
A Study to Assess Drug Levels, Tolerability and Absolute Biological Availability of Single-dose of BMS-986446 in Healthy Participants
The purpose of this study is to assess drug levels, tolerability and absolute biological availability of single subcutaneous dose of BMS-986446 in healthy participants
- Trial name
- NCT06955741
- Testing
- BMS-986446 IV, BMS-986446 SC, Acetaminophen
- Where
- 2 sites in United States
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Atherosclerosis
Comparison Of Two Tablet Formulations Of SB-568859
SB-568859 is a medication that is being developed for the treatment of atherosclerosis (hardening of the arteries). The purpose of this study is to see if there is a difference in how the human body takes up the study drug…
- Trial name
- NCT00470145
- Testing
- SB-568859
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Safety, Tolerability, Pharmacokinetics of AEF0217
AEF0217 First-in-Human Phase I Study in 3 Parts (Single and Multiple Ascending Doses, and Food Effect) in Healthy Subjects.
This trial is divided in 3 parts: FIH-SAD (Single Ascending Doses), FIH-MAD (Multiple Ascending Doses) and FIH-FE (Food effects). FIH-SAD will start first.
- Trial name
- AEF0217-101 (NCT05170737)
- Testing
- AEF0217
- Where
- Spain
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Aelis Farma
Infection, Human Immunodeficiency Virus, HIV Infections
A Two-part Study to Compare a Tablet and Capsule Formulation of GSK2838232 With and Without Food, and to Assess the Safety and Drug Levels of Repeated Once-daily Doses of GSK2838232 Without Ritonavir
This study will be conducted in two Parts to confirm the acceptability/selection of a tablet formulation for future clinical development of GSK2838232.
- Trial name
- NCT03234036
- Testing
- GSK2838232 100 mg tablet, GSK2838232 50 mg capsule, Ritonavir 100 mg tablets
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Rhinitis, Allergic, Perennial and Seasonal
A Relative Bioavailability Study of Fluticasone Furoate and Levocabastine
This is an open label, randomized, 3-way cross-over, and repeat administration study in healthy male and female subjects. The purpose of the study is to determine the relative bioavailability of Fluticasone Furoate (FF) and…
- Trial name
- NCT01962467
- Testing
- FF/LEV FDC, FF, LEV
- Where
- Australia
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Infections, Bacterial
A Three-part Study to Determine the Safety, Tolerability and Pharmacokinetics of GSK1322322 in Healthy Volunteers and Healthy Male Japanese Subjects
The primary objectives of this study are to assess the safety, tolerability and pharmacokinetics of GSK1322322 following intravenous (IV) and oral administration.
- Trial name
- NCT01818011
- Testing
- GSK1322322 Initial fit for purpose tablets, GSK1322322 over granulated tablets, GSK1322322 intended commercial tablets
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Major Depressive Disorder
A Study of a Psilocybin Analog (CYB003) in Healthy Participants With and Without Major Depressive Disorder
The purpose of this study is to determine the safety and tolerability of ascending oral doses of CYB003 in healthy participants with and without major depressive disorder (MDD).
- Trial name
- NCT05385783
- Testing
- CYB003, Psychotherapy, Psychological Support
- Where
- 3 sites in United States
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Cybin IRL Limited
Healthy
Oral Cyanocobalamin (Eligen B12) Bioavailability Study
The purpose of this study is to assess and compare the pharmacokinetics (PK) of cyanocobalamin after the oral administration of Eligen® B12 (cyanocobalamin/SNAC), oral cyanocobalamin alone (commercially-available formulation) and…
- Trial name
- NCT01311739
- Testing
- Cyanocobalamin
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Emisphere Technologies, Inc.